Covalent probes can display unmatched potency, selectivity, and duration of action; however, their discovery is challenging. In principle, fragments that can irreversibly bind their target can overcome the low affinity that limits reversible fragment screening, but such electrophilic fragments were considered nonselective and were rarely screened. We hypothesized that mild electrophiles might overcome the selectivity challenge and constructed a library of 993 mildly electrophilic fragments. We characterized this library by a new high-throughput thiol-reactivity assay and screened them against 10 cysteine-containing proteins. Highly reactive and promiscuous fragments were rare and could be easily eliminated. In contrast, we found hits for most targets. Combining our approach with high-throughput crystallography allowed rapid progression to potent and selective probes for two enzymes, the deubiquitinase OTUB2 and the pyrophosphatase NUDT7. No inhibitors were previously known for either. This study highlights the potential of electrophile-fragment screening as a practical and efficient tool for covalent-ligand discovery.
Journal article
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Journal of the American Chemical Society, Vol.141(22), pp.8951-8968
05/Jun/2019
Abstract
Details
- Title
- Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
- Creators
- Efrat Resnick (null) - The Weizmann Institute of ScienceAnthony Bradley (null) - University of OxfordJinrui Gan (null) - The Weizmann Institute of ScienceAlice Douangamath (null) - Diamond Light SourceTobias Krojer (null) - University of OxfordRitika Sethi (null) - University of OxfordPaul P. Geurink (null) - Leiden UniversityAnthony Aimon (null) - University of OxfordGabriel Amitai (null) - The Weizmann Institute of ScienceDom Bellini (null) - University of WarwickJames Bennett (null) - University of OxfordMichael Fairhead (null) - University of OxfordOleg Fedorov (null) - University of OxfordRonen Gabizon (null) - The Weizmann Institute of ScienceJin Gan (null) - Leiden UniversityJingxu Gu (null) - University College London (United Kingdom, London) - UCLAlexander Plotnikov (null) - The Weizmann Institute of ScienceNava Reznik (null) - 972WIS_INST___120Gian Filippo Ruda (null) - University of OxfordLaura Diaz-Saez (null) - University of OxfordVerena M. Straub (null) - University of OxfordTamas Szommer (null) - University of OxfordSrikannathasan Velupillai (null) - University of OxfordDaniel Zaidman (null) - The Weizmann Institute of ScienceYanling Zhang (null) - Tsinghua UniversityAlun R. Coker (null) - University College London (United Kingdom, London) - UCLChristopher G. Dowson (null) - University of WarwickHaim M. Barr (null) - The Weizmann Institute of ScienceChu Wang (null) - Tsinghua UniversityKilian V. M. Huber (null) - University of OxfordPaul E. Brennan (null) - University of OxfordHuib Ovaa (null) - Leiden UniversityFrank von Delft (null) - University of OxfordNir London (Corresponding Author) - The Weizmann Institute of Science
- Resource Type
- Journal article
- Publication Details
- Journal of the American Chemical Society, Vol.141(22), pp.8951-8968; 05/Jun/2019
- Number of pages
- 18
- Language
- English
- DOI
- https://doi.org/10.1021/jacs.9b02822
- Grant note
- N.L. is the incumbent of the Alan and Laraine Fischer Career Development Chair. N.L. wishes to acknowledge funding from the Israel Science Foundation (Grant No. 1097/16), The Rising Tide Foundation, The Israel Cancer Research Foundation, and the Israeli Ministry of Science and Technology (Grant No. 3-14763). This work was supported by the Dutch Organization for Scientific Research NWO (VICI grant 724.013.002 to H.O.) We thank Yves Leestemaker for assistance with the DUB ABPP assays. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, the Canada Foundation for Innovation, the Eshelman Institute 22 for Innovation, Genome Canada through Ontario Genomics Institute (OGI-055)], the Innovative Medicines Initiative (EU/EFPIA) (ULTRA-DD Grant No. 115766), Janssen, Merck KGaA (Darmstadt, Germany), MSD, Novartis Pharma AG, the Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, Sao Paulo Research Foundation-FAPESP, Takeda, and Wellcome (106169/Z/14/Z). Supported by a research grant from the Nancy and Stephen Grand Israel National Center for Personalized Medicine. We thank Ilana Berlin for providing the GFP-OTUB2 plasmids. We thank Prof. Deborah Fass for the generous gift of QSOX1 protein.
- Record Identifier
- 993263844203596
Metrics
7 Record Views